Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2008, Vol. 6 ›› Issue (2): 128-133.doi: 10.3736/jcim20080205

• Original Clinical Research • Previous Articles     Next Articles

Effectiveness of Danning Tablet in patients with non-alcoholic fatty liver of damp-heat syndrome type: A multicenter randomized controlled trial

Guang Ji1(), Jian-gao Fan2, Jian-jie Chen3, Lun-gen Lu4, Lian-jun Xing1, Pei-yong Zheng5, Hong-gang Gu1, Hua-feng Wei1, Sheng-fu You1, Pei-ting Zhu1   

  1. 1. Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
    2. Department of Gastroenterology, Shanghai First Peoples Hospital, Shanghai Jiaotong University, Shanghai 200080, China
    3. Department of Hepatology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
    4. Shanghai Institute of Digestive Diseases, Shanghai 200000, China
    5. Evaluation Center of Clinical Efficacy, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
  • Received:2007-04-11 Online:2008-02-20 Published:2008-02-15
  • Contact: JI Guang

Objective:To evaluate the efficacy and safety of Danning Tablet (DNT) in patients with non-alcoholic fatty liver disease (NAFLD) of damp-heat syndrome type.

Methods:A multicenter, randomized, double-blinded and positive drug parallel controlled trial was performed. One hundred and thirty-five patients were enrolled into the study and divided into two groups: DNT-treated group (n=102) and ursodeoxycholic acid (UDCA)-treated group (n=33). Body mass index (BMI), principal symptoms, liver function, blood lipids, iconographic, and compositional parameters were measured before and after treatment, respectively.

Results:In the two groups, BMI, distress in hepatic region, fatigue, anorexia, liver function, blood lipids and iconographic parameters were significantly improved, and the improvements of BMI, distress in hepatic region were better in DNT-treated group than in UDCA-treated group. The histological study also showed that DNT had positive effect in treatment of NAFLD.

Conclusion:DNT is an effective drug to treat patients with NAFLD of damp-heat syndrome type and is more effective than UDCA.

Key words: fatty liver, dampness-heat (traditional Chinese medicine), treatment effectiveness, randomized controlled trial

CLC Number: 

  • R657.31


Group n Main symptom score Body mass index
Pre-treatment 107 7.28±4.31 26.38±4.33
Post-treatment 107 5.09±3.98 24.65±3.86
Difference 107 2.19±1.30* 1.73±0.84*
Pre-treatment 33 7.14±4.66 25.94±6.36
Post-treatment 33 5.58±4.32 25.08±3.47
Difference 33 1.56±1.50 0.86±0.92


Group n ALT (U/L) AST (U/L) GGT (U/L) TG (mmol/L) TC (mmol/L)
Pre-treatment 102 71.19±41.00 55.31±23.86 86.41±47.96 3.20±1.76 5.32±1.25
Post-treatment 102 40.54±21.29* 31.16±11.92* 46.50±27.68* 2.46±1.40* 5.03±0.83
Pre-treatment 33 74.13±39.21 61.7726.09 81.2346.84 3.502.29 5.391.44
Post-treatment 33 48.69±25.20* 33.94±16.43* 56.13±38.30* 2.65±1.20* 5.22±1.32


Group n Degree of improvement in B-ultrasound image n Degree of improvement in CT image
+ ++ +++ + ++ +++
DNT-treated 102 11 68 19 4 52 2 30 18 22
UDCA-treated 33 5 22 6 0 18 2 10 6 0
[1] Tagle Arrospide M . Non-alcoholic fatty liver. Rev Gastroenterol Peru. 2003; 23(1):49-57.
[2] Alba LM, Lindor K . Non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2003; 17(8):977-986.
doi: 10.1046/j.1365-2036.2003.01493.x
[3] Angulo P, Lindor KD . Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002; 17:186-190.
[4] Gronbaek H, Eivindson MV, Hamilton-Dutoit S , et al. Nonalcoholic steatohepatitis—a new hepatic disease . Ugeskr Laeger. 2003; 165(11):1115-1118.
doi: 10.1055/s-2007-1007111 pmid: 12677985
[5] Mulhall BP, Ong JP, Younossi ZM . Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol. 2002; 17(11):1136-1143.
doi: 10.1046/j.1440-1746.2002.02881.x pmid: 12453271
[6] Alvarez-Martinez H, Perez-Campos E . Non-alcoholic steatohepatitis. Rev Gastroenterol Mex. 2002; 67(2):118-125.
[7] Linhart HG . Non-alcoholic steato-hepatitis. Schweiz Rundsch Med Prax. 2000; 89(22):963-966.
doi: 10.1016/j.bpg.2010.07.003 pmid: 10893995
[8] de Knegt RJ . Non-alcoholic steatohepatitis : clinical significance and pathogenesis. Scand J Gastroenterol Suppl. 2001; ( 234):88-92.
doi: 10.1080/003655201753265505 pmid: 11768567
[9] Dixon JB, Bhathal PS , O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001; 121(1):91-100.
doi: 10.1053/gast.2001.25540
[10] Angulo P, Keach JC, Batts KP , et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999; 30(6):1356-1362.
doi: 10.1002/(ISSN)1527-3350
[11] Angulo P . Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16):1221-1231.
[12] Angulo P, Lindor KD . Insulin resistance and mitochondrial abnormalities in NASH : a cool look into a burning issue. Gastroenterology. 2001; 120(5):1281-1285.
doi: 10.1053/gast.2001.23591 pmid: 11266392
[13] Sanyal AJ, Campbell-Sargent C, Mirshahi F , et al. Nonalcoholic steatohepatitis : association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001; 120(5):1183-1192.
doi: 10.1053/gast.2001.23256
[14] Cttrim HP, Parana R, Braga E , et al. Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? AmJ Gastroenterol. 2000; 95(10):3018-3019.
doi: 10.1016/S0002-9270(00)02034-7 pmid: 11051414
[15] Tell MR, James OF, Burt AD , et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995; 22(6):1714-1719.
doi: 10.1002/hep.1840220616 pmid: 7489979
[16] Matteoni CA, Younossi ZM, Gramlich T , et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116(6):1413-1419.
doi: 10.1016/S0016-5085(99)70506-8 pmid: 10348825
[17] Ratziu V, Bonyhay L, Di Martino V , et al. Survival, liver failure,and hepatocellular carcinoma in obesity- related cryptogenic cirrhosis. Hepatology. 2002; 35(6):1485-1493.
doi: 10.1053/jhep.2002.33324 pmid: 12029634
[18] Ratziu V, Giral P, Charlotte F , et al. Liver fibrosis in overweight patients. Gastroenterology. 2000; 118(6):1117-1123.
doi: 10.1016/S0016-5085(00)70364-7 pmid: 10833486
[19] Fan JG . Steatohepatitis studies in China. Shi Jie Hua Ren Xiao Hua Za Zhi. 2001; 9(1):6-10. Chinese.
doi: 10.3969/j.issn.1009-3079.2001.01.002
范建高 . 中国脂肪肝的研究.世界华人消化杂志. 2001; 9(1):6-10.
doi: 10.3969/j.issn.1009-3079.2001.01.002
[20] Yin M, Wheeler MD, Kono H , et al. Essential role of tumor necrosis factor a in alcohol induced liver injury in mice. Gastroenterology. 1999; 117(4):942-952.
doi: 10.1016/S0016-5085(99)70354-9 pmid: 10500078
[21] You P , Liu YL. Research progress of nonalcoholic steatohepatitis pathology. Zhongguo Yi Yao Dao Kan. 2003; 5(2):97-99. Chinese.
尤鹏, 刘玉兰 . 非酒精性脂肪肝炎发病机制的研究进展.中国医药导刊. 2003; 5(2):97-99.
[22] Angulo P . Current best treatment for non-alcoholic fatty liver disease. Expert Opin Pharmacother. 2003; 4(5):611-623.
doi: 10.1517/14656566.4.5.611
[23] Hookman P, Barkin JS . Current biochemical studies of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) suggest a new therapeutic approach. Am J Gastroenterol. 2003; 98(2):495-499.
[24] Sanyal AJ . Treatment of non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002; 17(Suppl 3):S385-S388.
[25] Oneta CM, Dufour JF . Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations. Swiss Med Wkly. 2002; 132(35-36):493-505.
pmid: 12506331
[26] Angulo P, Lindor KD . Treatment of non-alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol. 2002; 16(5):797-810.
doi: 10.1053/bega.2002.0327 pmid: 12406446
[27] Angulo P, Lindor KD . Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis. 2001; 21(1):81-88.
doi: 10.1055/s-2001-12931 pmid: 11296699
[28] Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology , Chinese Medical Association. Diagnostic standard of non-alcoholic fatty liver ( Draft) . Zhonghua Gan Zang Bing Za Zhi. 2001; 9(6):325. Chinese.
中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪肝诊断标准(草案).中华肝脏病杂志. 2001; 9(6):325.
[29] Zheng XY. Guiding principles of clinical research on new drugs of traditional Chinese medicine. Beijing: China Medico-Pharmaceutical Science and Technology Publishing House. 2002: 88-89. Chinese.
郑筱萸 . 中药新药临床研究指导原则.北京: 中国医药科技出版社. 2002: 88-89.
[30] Laurin J, Lindor KD, Crippin JS , et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic steatohepatitis: A pilot study. Hepatology. 1996; 23(6):1464-1467.
doi: 10.1002/(ISSN)1527-3350
[31] Caldwell SH, Oelsner DH, Iezzoni JC , et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999; 29(3) : 664-669.
doi: 10.1002/hep.510290347 pmid: 10051466
[32] Bugianesi E, Leone N, Vanni E , et al. Expanding the natural history of nonalcoholic steatohepatitis : from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002; 123(1):134-140.
doi: 10.1053/gast.2002.34168
[33] Angulo P . Use of ursodeoxycholic acid in patients with liver disease. Curr Gastroenterol Rep. 2002; 4(1):37-44.
doi: 10.1007/s11894-002-0036-9 pmid: 11825540
[34] Kobak GE, Deutsch G, Dahl R , et al. Fat-laden hepa- tocytes are more prone to cellular necrosis than apoptosis when exposed to hydrophobic bile acids. Gastroenterology Suppl. 2002; 122:A642.
[35] Pasha T , Heathcote J, Gabriel S, et al. Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology. 1999; 29(1):21-26.
doi: 10.1002/(ISSN)1527-3350
[36] Zhu PT, Zhang JZ, Wang YS, et al. Treatment of chronic biliary tract infection and gallstone diseases with Dan Ning Tab, Hitrechol and UDCA (A comparative clinical trial). Zhongguo Zhong Xi Yi Jie He Wai Ke Za Zhi. 1995; 1(4):205-209. Chinese with abstract in English.
朱培庭, 张静哲, 王以实 , 等. 胆宁片、胆通、熊去氧胆酸治疗慢性胆道感染、胆石病的临床疗效对照研究.中国中西医结合外科杂志. 1995; 1(4):205-209.
[37] Ji G , Zheng PY. Commentary on research of fatty liver treated by traditional Chinese medicine. Zhong Yi Yao Xue Kan. 2004; 22(1):87-88, 102. Chinese.
doi: 10.3969/j.issn.1673-7717.2004.01.042
季光, 郑培永 . 中医药治疗脂肪肝的研究评述.中医药学刊. 2004; 22(1):87-88, 102.
doi: 10.3969/j.issn.1673-7717.2004.01.042
[38] Fan JG, Zhong L, Wang GL , et al. Influence of ursodeoxycholic acid on the therapeutic effects of low- calorie diet in obesity and hyperlipidemia rats with stearohepatitis. Zhonghua Gan Zang Bing Za Zhi. 2002; 10(1):43-45. Chinese with abstract in English.
doi: 10.3760/j.issn:1007-3418.2002.01.013
范建高, 钟岚, 王国良 , 等. 熊去氧胆酸对节制饮食防治大鼠肥胖高脂血症性脂肪性肝炎的影响.中华肝脏病杂志. 2002; 10(1):43-45.
doi: 10.3760/j.issn:1007-3418.2002.01.013
[39] Fan JG , Liu HY. Multi-center clinical study on nonalcoholic fatty liver treated by Danning tablet. Guo Wai Yi Xue Xiao Hua Xi Ji Bing Feng Ce. 2004; 24(2):124-126. Chinese with abstract in Englsih.
doi: 10.3969/j.issn.1673-534X.2004.02.019
范建高, 刘厚钰 . 胆宁片治疗非酒精性脂肪性肝病的多中心临床试验.国外医学消化系疾病分册. 2004; 24(2):124-126.
doi: 10.3969/j.issn.1673-534X.2004.02.019
[1] Chiung-Hui Huang, Mei-Ling Yeh, Fang-Pey Chen, Daphne Wu. Low-level laser acupuncture reduces postoperative pain and morphine consumption in older patients with total knee arthroplasty: A randomized placebo-controlled trial. Journal of Integrative Medicine, 2022, 20(4): 321-328.
[2] Maryam Azimi, Hanieh Niayesh, Mahboobeh Raeiszadeh, Sedigheh Khodabandeh-shahraki. Efficacy of the herbal formula of Foeniculum vulgare and Rosa damascena on elderly patients with functional constipation: A double-blind randomized controlled tria. Journal of Integrative Medicine, 2022, 20(3): 230-236.
[3] Ubiratan Cardinalli Adler, Maristela Schiabel Adler, Ana Elisa Madureira Padula, Livia Mitchiguian Hotta, Amarilysde Toledo Cesar, José Nelson Martins Diniz, Helen de Freitas Santos, Edson Zangiacomi Martinez. Homeopathy for COVID-19 in primary care: A randomized, double-blind, placebo-controlled trial (COVID-Simile study). Journal of Integrative Medicine, 2022, 20(3): 221-229.
[4] Xin Wang, Wen-juan Song, Yi Ruan, Bing-chu Li, Can Lü, Nian Huang, Fan-fu Fang, Wei Gu. Core muscle functional strength training for reducing the risk of low-back pain in military recruits: An open-label randomized controlled trial. Journal of Integrative Medicine, 2022, 20(2): 145-152.
[5] Meng-ya Shan, Ying Dai, Xiao-dan Ren, Jing Zheng, Ke-bin Zhang, Bin Chen, Jun Yan, Zi-hui Xu. Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis. Journal of Integrative Medicine, 2021, 19(6): 545-554.
[6] Mao-xing Pan, Chui-yang Zheng, Yuan-jun Deng, Kai-rui Tang, Huan Nie, Ji-qian Xie, Dong-dong Liu, Gui-fang Tu, Qin-he Yang, Yu-pei Zhang. Hepatic protective effects of Shenling Baizhu powder, a herbal compound, against inflammatory damage via TLR4/NLRP3 signalling pathway in rats with nonalcoholic fatty liver disease . Journal of Integrative Medicine, 2021, 19(5): 428-438.
[7] Meng-zhu Zhao, Chen Zhao, Shuang-shuang Tu, Xu-xu Wei, Hong-cai Shang. Evaluating the methodology of studies conducted during the global COVID-19 pandemic: A systematic review of randomized controlled trials. Journal of Integrative Medicine, 2021, 19(4): 317-326.
[8] Si-chun Gu, Jie Zhou, Qing Ye, Can-xing Yuan. Pingchan granule for depressive symptoms in Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Journal of Integrative Medicine, 2021, 19(2): 120-128.
[9] Jie Wu, Shu-wei Duan, Hong-tao Yang, Yue-yi Deng, Wei Li, Ya-ni He, Zhao-hui Ni, Yong-li Zhan, Shan Lin, Zhi-yong Guo, Jun Zhu, Jing-ai Fang, Xu-sheng Liu, Li-hua Wang, Rong Wang, Nian-song Wang, Xiao-hong Cheng, Li-qun He, Ping Luo, Shi-ren Sun s, Ji-feng Sun, Ai-ping Yin, Geng-ru Jiang, Hong-yu Chen, Wen-hu Liu, Hong-li Lin, Meng Liang, Lu Ma, Ming Chen, Li-qun Song, Jian Chen, Qing Zhu, Chang-ying Xing, Yun Li, Ji-ning Gao, Rong-shan Li, Ying Li, Hao Zhang, Ying Lu, Qiao-ling Zhou, Jun-zhou Fu, Qiang He, Guang-yan Cai, Xiang-mei Chen. Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trial. Journal of Integrative Medicine, 2021, 19(2): 111-119.
[10] Xian Wang, Xuan Yin, Xiu-tian Guo, Yan Wang, Wen-qi Jin, Ai-jun Mao, Lixing Lao, Zhang-jin Zhang, Jie Zhang, Shi-fen Xu. Effects of the pestle needle therapy, a type of acupoint stimulation, on post-hemorrhoidectomy pain: A randomized controlled trial. Journal of Integrative Medicine, 2020, 18(6): 492-498.
[11] Sherman Gu, Arthur Yin Fan. Controversial conclusions from two randomized controlled trials for acupuncture's effects on polycystic ovary syndrome or in vitro fertilization support. Journal of Integrative Medicine, 2020, 18(2): 89-91.
[12] Gerli E.G. Herr, Fábio Goulart da Silva, Francisco José Cidral-Filho, Fabricia Petronilho, Lucinéia Gainski Danielski, Mariana Pereira de Souza Goldim, Afonso Shiguemi Inoue Salgado, Franciane Bobinski, Daniel Fernandes Martins, Eliane R. Winkelmann. Effects of the use of bioceramic wraps in patients with lower limb venous ulcers: A randomized double-blind placebo-controlled trial. Journal of Integrative Medicine, 2020, 18(1): 27-.
[13] Xin-yu Yue, Zhuo-qi Feng, Xi-yi Yu, Jia-min Hu, Xiao-Jing He, Shi Shu. Fire-needle acupuncture for upper limb spastic paralysis after stroke: Study protocol for a randomized controlled trial. Journal of Integrative Medicine, 2019, 17(3): 167-172.
[14] Pádraic J.Dunne, Julie Lynch, Lucia Prihodova, Caoimhe O'Leary, Atiyeh Ghoreyshi, Sharee A. Basdeo, Donal J.Cox, Rachel Breen, Ali Sheikhi, Áine Carroll, Cathal Walsh, Geraldine McMahon, Barry White. Burnout in the emergency department: Randomized controlled trial of an attention-based training program. Journal of Integrative Medicine, 2019, 17(3): 173-180.
[15] Ya-ru Huangfu, Wei Peng, Bao-jun Guo, Zhi-fu Shen, Li Li, Shi-wei, Liu, Hui Zheng, You-ping Hu. Effects of acupuncture in treating insomnia due to spleen-stomach disharmony syndrome and its influence on intestinal microbiome: Study protocol for a randomized controlled trial. Journal of Integrative Medicine, 2019, 17(3): 161-167.
Full text



[1] Wei-xiong Liang. Problems-solving strategies in clinical treatment guideline for traditional Chinese medicine and integrative medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 1-4
[2] Zhao-guo Li. Discussion on English translation of commonly used sentences in traditional Chinese medicine: part one. Journal of Chinese Integrative Medicine, 2008, 6(1): 107-110
[3] Jun Hu, Jian-ping Liu. Non-invasive physical treatments for chronic/recurrent headache. Journal of Chinese Integrative Medicine, 2008, 6(1): 31
[4] Xue-mei Liu, Qi-fu Huang, Yun-ling Zhang, Jin-li Lou, Hong-sheng Liu, Hong Zheng. Effects of Tribulus terrestris L. saponion on apoptosis of cortical neurons induced by hypoxia-reoxygenation in rats. Journal of Chinese Integrative Medicine, 2008, 6(1): 45-50
[5] . Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication (Chinese version, part two). Journal of Chinese Integrative Medicine, 2010, 8(11): 1001-1005
[6] Daniel Weber, Janelle M Wheat, Geoffrey M Currie. Inflammation and cancer: Tumor initiation, progression and metastasis,and Chinese botanical medicines. Journal of Chinese Integrative Medicine, 2010, 8(11): 1006-1013
[7] Hong Liu , Guo-liang Zhang, Li Shen , Zhen Zeng, Bao-luo Zhou, Cheng-hai Liu, Guang Nie . Application and evaluation of a pseudotyped virus assay for screening herbs for anti-H5Nl avian influenza virus. Journal of Chinese Integrative Medicine, 2010, 8(11): 1036-1040
[8] Zhao-guo Li . A discussion of English translation of 1995 and 1997 Chinese National Standards of Traditional Chinese Medical Terminologies for Clinical Diagnosis and Treatment. Journal of Chinese Integrative Medicine, 2010, 8(11): 1090-1096
[9] Rui Jin, Bing Zhang. A complexity analysis of Chinese herbal property theory: the multiple formations of herbal property (Part 1). Journal of Chinese Integrative Medicine, 2012, 10(11): 1198-1205
[10] Hui-min Liu, Xian-bo Wang, Yu-juan Chang, Li-li Gu. Systematic review and meta-analysis of randomized controlled trials of integrative medicine therapy for treatment of chronic severe hepatitis. Journal of Chinese Integrative Medicine, 2012, 10(11): 1211-1228